Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 5-(Methoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (CAS: 37746-78-4) with high quality, commercial production. We can provide COA, worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com
| Chemical Name |
5-(Methoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione |
| Synonyms |
5-(Methoxymethylene) Meldrum's Acid; Cabozantinib Impurity 56; Lenvatinib Impurity 79 |
| CAS Number |
37746-78-4 |
| CAT Number |
RF-PI1967 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C8H10O5 |
| Molecular Weight |
186.16 |
| Melting Point |
132.0~134.0℃ |
| Density |
1.297±0.06 g/cm3 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
Yellow Powder |
| 1 H NMR Spectrum |
Consistent With Structure |
| Purity / Analysis Method |
>97.0% (HPLC) |
| Total Impurities |
<3.00% |
| Test Standard |
Enterprise Standard |
| Usage |
Intermediate of Lenvatinib Mesylate (CAS: 857890-39-2)
|
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
5-(Methoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (CAS: 37746-78-4) is an intermediate of Lenvatinib Mesylate (CAS: 857890-39-2). Lenvatinib is a thyroid cancer drug developed by Eisai Corporation of Japan (Code: E7080), belonging to the inhibitor of oral multi-receptor tyrosine kinase (RTK) and can inhibit the kinase activity of the vascular endothelial growth factor (VEGF) Receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib can also inhibit the involvement of other RTKs in pathological angiogenesis, tumor growth, and cancer progression except for their normal cellular functions including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet-derived growth factor receptor (PDGFR [alpha]), KIT, and RET. [Indications]: Lenvatinib is suitable for the treatment of patients of thyroid cancer of local recurrence or metastasis type, progressivity type and radioactive iodine-refractory differentiated type. On February 13, 2015, the US FDA approved anticancer drug Lenvatinib for the treatment of thyroid cancer. Lenvatinib is a multi-target enzyme inhibitor, being capable of inhibiting the VEGFR2 and VEGFR3 (vascular endothelial growth factor receptor). The trade name of Lenvatinib is Lenvima. On May 20, 2015, the European Medicines Agency (EMA) approved Lenvatinib for the treatment of invasive, locally advanced or metastatic differentiated (papillary, follicular, Hurthle type) thyroid cancer (DTC). In the trial, the median survival time for patients of radioactive iodine-refractory DTC treated with Lenvatinib was 18 months while the value for patients who take placebo is only 3 months.